Cayce Nawaf, MD, Author at Grand Rounds in Urology

Cayce Nawaf, MD

SSM Health

Bridgeton, Missouri

Cayce Nawaf, MD, is a Urologist at SSM Health in Bridgeton, Missouri. Dr. Nawaf specializes in urologic oncology, including kidney, bladder, prostate, testes, adrenal, and ureteral tumors. He also diagnoses and treats other urologic conditions such as benign prostate hypertrophy, kidney stone disease, erectile dysfunction, and hematuria.

Dr. Nawaf earned his medical degree and completed his internship at the University of Tennessee in Memphis. He then completed his residency in General Surgery and served a research fellow at Yale University in New Haven, Connecticut. Dr. Nawaf completed a fellowship in Urological Oncology at Washington University in St. Louis, Missouri.

Talks by Cayce Nawaf, MD

Guidance for New Hires and Learning the Tricks of the Trade

Cayce Nawaf, MD | Aug 2024

Cayce Nawaf, MD, provides comprehensive guidance for new medical hires, focusing on the essential skills and strategies necessary for success. Emphasizing the importance of continuous learning and adaptability, Dr. Nawaf outlines key practices that new medical professionals should adopt to excel in their careers.

Dr. Nawaf underscores the importance of mentorship, effective communication, continuous learning, and ethical practice. By adopting these principles, new hires can build a successful and fulfilling career in the medical field, contributing to the advancement of healthcare and improving patient outcomes.

Endoscopic Management of Upper Tract UC and the Role of Mitomycin

Cayce Nawaf, MD | May 2024

Cayce Nawaf, MD, discusses the relationship between mitomycin and endoscopic management of upper tract urothelial carcinoma (UC). Dr. Nawaf begins with a quick overview of upper tract UC, noting that it is relatively rare.

Dr. Nawaf then compares the outcomes of endoscopic management against those of nephroureterectomy. He illustrates the 5- and 10- year oncologic outcomes from both treatments, demonstrating the similarities between grade groups and presenting the AUA guidelines as additional support.

Dr. Nawaf addresses concerns regarding agent delivery methods to the kidney, and presents examples of nephrostomy tubes, double pigtail stents, and ureteral catheters. He presents data from the OLYMPUS Trial supporting the efficacy of retrograde delivery via ureteral catheter.

Regarding agents, Dr. Nawaf presents data on the efficacy of mitomycin While 58.8-61% of patients had a complete response to the treatment, he notes that there are moderate to severe side effects and caveats around endoscopic management of upper tract UC with mitomycin.

He concludes with a step-by-step guide to using mitomycin in treatment. Dr. Nawaf underscores the importance of selecting patients correctly for treatment based on disease grade and patient preference.